Risk Assessment of Amiodarone Use in Patients with Cirrhosis and Heart Failure

The amiodarone therapy in patients with underlying cirrhosis and heart failure may be reasonable with close liver function monitoring if the benefits outweigh the risks of amiodarone therapy.

Authors

Institutions

Publication Details

Journal
Current Drug Safety
Published
2025-05-08
DOI
https://doi.org/10.2174/0115748863361411250419155302
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risk Assessment of Amiodarone Use in Patients with Cirrhosis and Heart Failure

Abdullah Al Mamun, Kazuhiko Kido
Current Drug Safety
Heart Failure Treatment and Management
article

Risk Assessment of Amiodarone Use in Patients with Cirrhosis and Heart Failure

Abdullah Al Mamun, Kazuhiko Kido
article en

Abstract

The amiodarone therapy in patients with underlying cirrhosis and heart failure may be reasonable with close liver function monitoring if the benefits outweigh the risks of amiodarone therapy.

Current Drug SafetyVol. 20
West Virginia University (US)
Good health and well-being
Openalex Percentile: Top 82%
Heart Failure Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Risk Assessment of Amiodarone Use in Patients with Cirrhosis and Heart Failure — Abdullah Al Mamun, Kazuhiko Kido · Current Drug Safety (2025) | TGRS Research Map | TGRS